

Deep Phenotyping of CIndU

NCT07359430

Status	RECRUITING
Sponsor	Centre for Human Drug Research, Netherlands
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (18)

- Healthy volunteers
 - Male and female subjects between 18-69 years of age; in general, stable good health as per judgement of the investigator based upon the results of a medical history, physical examination and vital signs.
 - No clinically significant skin disease in the research area
 - No history of hypertrophic scarring or keloid.
 - Willing to give written informed consent and willing and able to comply with the study protocol.
- ... and 13 more (see full listing online)

Exclusion (27)

- Significant, uncontrolled or unstable disease in any organ system as per judgment of the investigator (regardless of association with the immunosuppressing disorder/therapy), including but not limited to: psychiatric, neurologic, cardiovascular, pulmonary, gastrointestinal, hepatic, renal, endocrine, hematologic or respiratory disease.
 - History of immunological abnormality (e.g., immune suppression) that may interfere with study objectives, in the opinion of the investigator.
 - Loss or donation of blood over 500 mL within three months prior to screening.
 - Positive hepatitis B surface antigen (HbsAg), hepatitis C antibody (HCV ab), or human immunodeficiency virus antibody (HIV ab) at screening
 - Known infection requiring (topical or oral) antibiotic therapy within 56 days prior to Day 1.
- ... and 22 more (see full listing online)

Locations (3 total)

Centre for Human Drug Research, Leiden, South Holland, Netherlands
Erasmus Medical Center, Rotterdam, South Holland, Netherlands
University Medical Center Utrecht, Utrecht, Utrecht, Netherlands